$EYPT
EyePoint Pharmaceuticals, Inc.

2013 Q1 Form 10-Q Financial Statement

#000119312513045326 Filed on February 08, 2013

View on sec.gov

Income Statement

Concept 2013 Q1 2012 Q4 2011 Q4
Revenue $513.0K $585.0K $630.0K
YoY Change -4.65% -7.14% 52.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.740M $1.660M $1.450M
YoY Change -1.14% 14.48% -27.5%
% of Gross Profit
Research & Development $1.587M $1.575M $1.992M
YoY Change 5.24% -20.93% 30.2%
% of Gross Profit
Depreciation & Amortization $250.0K $250.0K $870.0K
YoY Change 8.7% -71.26% 4.82%
% of Gross Profit
Operating Expenses $3.325M $3.233M $18.27M
YoY Change 1.84% -82.31% 416.19%
Operating Profit -$2.812M -$2.648M -$17.64M
YoY Change 3.12% -84.99% 465.3%
Interest Expense $0.00 $0.00 $140.0K
YoY Change -100.0% -100.0% -69.57%
% of Operating Profit
Other Income/Expense, Net $3.000K $3.000K $139.0K
YoY Change -72.73% -97.84%
Pretax Income -$2.809M -$2.645M -$17.50M
YoY Change 3.42% -84.89% 558.05%
Income Tax -$15.00K -$37.00K -$44.00K
% Of Pretax Income
Net Earnings -$2.794M -$2.608M -$17.46M
YoY Change 4.02% -85.06% 547.87%
Net Earnings / Revenue -544.64% -445.81% -2771.43%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.197M -$1.120M -$8.394M
COMMON SHARES
Basic Shares Outstanding 23.30M shares 23.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q1 2012 Q4 2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.70M $15.70M $18.70M
YoY Change -16.97% -16.04% 28.08%
Cash & Equivalents $7.998M $9.409M $8.408M
Short-Term Investments $5.700M $6.300M $10.30M
Other Short-Term Assets $500.0K $100.0K $200.0K
YoY Change 25.0% -50.0% 100.0%
Inventory
Prepaid Expenses
Receivables $1.000M $900.0K $1.000M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $15.21M $16.81M $19.90M
YoY Change -15.06% -15.53% 25.16%
LONG-TERM ASSETS
Property, Plant & Equipment $223.0K $277.0K $400.0K
YoY Change -44.25% -30.75% 300.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $100.0K $100.0K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $3.915M $4.232M $5.000M
YoY Change -20.1% -15.36% -78.07%
TOTAL ASSETS
Total Short-Term Assets $15.21M $16.81M $19.90M
Total Long-Term Assets $3.915M $4.232M $5.000M
Total Assets $19.12M $21.04M $24.90M
YoY Change -16.14% -15.49% -35.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $355.0K $215.0K $300.0K
YoY Change 18.33% -28.33% 50.0%
Accrued Expenses $1.437M $1.084M $700.0K
YoY Change 79.63% 54.86% -12.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.685M $2.083M $2.600M
YoY Change 3.27% -19.88% 62.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.200M $5.100M $4.500M
YoY Change 10.64% 13.33% -45.78%
Total Long-Term Liabilities $5.200M $5.100M $4.500M
YoY Change 10.64% 13.33% -45.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.685M $2.083M $2.600M
Total Long-Term Liabilities $5.200M $5.100M $4.500M
Total Liabilities $7.879M $7.232M $7.200M
YoY Change 7.93% 0.44% -28.71%
SHAREHOLDERS EQUITY
Retained Earnings -$259.7M -$256.9M
YoY Change
Common Stock $23.00K $23.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.24M $13.81M $17.80M
YoY Change
Total Liabilities & Shareholders Equity $19.12M $21.04M $24.90M
YoY Change -16.14% -15.49% -35.66%

Cashflow Statement

Concept 2013 Q1 2012 Q4 2011 Q4
OPERATING ACTIVITIES
Net Income -$2.794M -$2.608M -$17.46M
YoY Change 4.02% -85.06% 547.87%
Depreciation, Depletion And Amortization $250.0K $250.0K $870.0K
YoY Change 8.7% -71.26% 4.82%
Cash From Operating Activities -$1.970M -$1.780M -$2.360M
YoY Change -7.94% -24.58% 306.9%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$40.00K -$160.0K
YoY Change -50.0% -75.0% 220.0%
Acquisitions
YoY Change
Other Investing Activities $580.0K $2.900M $1.120M
YoY Change 383.33% 158.93% -153.08%
Cash From Investing Activities $560.0K $2.870M $960.0K
YoY Change 409.09% 198.96% -144.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -70.00K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -1.970M -1.780M -2.360M
Cash From Investing Activities 560.0K 2.870M 960.0K
Cash From Financing Activities 0.000 -70.00K 0.000
Net Change In Cash -1.410M 1.020M -1.400M
YoY Change -30.54% -172.86% -48.91%
FREE CASH FLOW
Cash From Operating Activities -$1.970M -$1.780M -$2.360M
Capital Expenditures -$10.00K -$40.00K -$160.0K
Free Cash Flow -$1.960M -$1.740M -$2.200M
YoY Change -7.55% -20.91% 315.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23297011 shares
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2083000
CY2012Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
142000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
6316000
CY2012Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
784000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-256917000
CY2012Q4 us-gaap Assets
Assets
21042000
CY2012Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
15156000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9409000
CY2012Q4 us-gaap Deferred Revenue
DeferredRevenue
5700000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21042000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23297011 shares
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
2.15
CY2012Q3 psdv Common Stock Warrant Exercise Price Per Share
CommonStockWarrantExercisePricePerShare
2.50
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8408000
CY2011Q4 psdv Unrecognized Tax Benefit
UnrecognizedTaxBenefit
0
CY2012Q4 us-gaap Other Assets
OtherAssets
72000
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1001000
CY2012Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
948000
CY2012Q4 us-gaap Liabilities
Liabilities
7232000
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1084000
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
277000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23297011 shares
CY2012Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
6311000
CY2012Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5149000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
16810000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
269703000
CY2012Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1400000
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
6311000
CY2012Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
13810000
CY2012Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3883000
CY2012Q4 us-gaap Available For Sale Securities Gross Unrealized Gain Loss
AvailableForSaleSecuritiesGrossUnrealizedGainLoss
-5000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
215000
CY2012Q4 psdv Unrecognized Tax Benefit
UnrecognizedTaxBenefit
0
CY2012Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2012Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 psdv Finite Lived Intangible Assets Remaining Useful Life
FiniteLivedIntangibleAssetsRemainingUsefulLife
5.0 Y
CY2012Q4 psdv Weighted Average Maturity
WeightedAverageMaturity
3.0 M
CY2012Q4 psdv Cash Equivalents Fair Value Disclosure
CashEquivalentsFairValueDisclosure
8845000
CY2012Q4 psdv Cash And Cash Equivalents And Marketable Securities Fair Value
CashAndCashEquivalentsAndMarketableSecuritiesFairValue
15700000
CY2012Q4 psdv Estimated Annual Amortization Of Intangible Assets
EstimatedAnnualAmortizationOfIntangibleAssets
780000
CY2012Q4 psdv Warrants Outstanding Weighted Average Remaining Contract Life
WarrantsOutstandingWeightedAverageRemainingContractLife
P3Y10M24D
CY2011Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12912000
CY2012Q2 us-gaap Other Assets
OtherAssets
77000
CY2012Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
942000
CY2012Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3178000
CY2012Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
421000
CY2012Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2176000
CY2012Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-251758000
CY2012Q2 us-gaap Assets
Assets
20597000
CY2012Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
14238000
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4625000
CY2012Q2 us-gaap Deferred Revenue
DeferredRevenue
6000000
CY2012Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20597000
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20802592 shares
CY2012Q2 us-gaap Common Stock Value
CommonStockValue
21000
CY2012Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2012Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
9954000
CY2012Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
967000
CY2012Q2 us-gaap Liabilities
Liabilities
6961000
CY2012Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
608000
CY2012Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2012Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
335000
CY2012Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20802592 shares
CY2012Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
9946000
CY2012Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3783000
CY2012Q2 us-gaap Assets Current
AssetsCurrent
15959000
CY2012Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
264431000
CY2012Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q2 us-gaap Available For Sale Securities Fair Value Disclosure
AvailableForSaleSecuritiesFairValueDisclosure
9946000
CY2012Q2 us-gaap Stockholders Equity
StockholdersEquity
13636000
CY2012Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4226000
CY2012Q2 us-gaap Available For Sale Securities Gross Unrealized Gain Loss
AvailableForSaleSecuritiesGrossUnrealizedGainLoss
-8000
CY2012Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
394000
CY2012Q2 psdv Cash Equivalents Fair Value Disclosure
CashEquivalentsFairValueDisclosure
4292000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
114000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
407000
us-gaap Investment Income Interest
InvestmentIncomeInterest
20000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4121000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1611000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-514000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20780000 shares
us-gaap Share Based Compensation
ShareBasedCompensation
642000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-4504000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
1103000
us-gaap Operating Income Loss
OperatingIncomeLoss
-20174000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-730000
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
14830000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-509000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-13000
us-gaap Net Income Loss
NetIncomeLoss
-19887000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
188000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3512000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
114000
us-gaap Royalty Revenue
RoyaltyRevenue
624000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20396000
us-gaap Operating Expenses
OperatingExpenses
22463000
us-gaap Revenues
Revenues
2289000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
161000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-38000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-99000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-5000
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
170000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
1665000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
380000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1652000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
5000
us-gaap Depreciation
Depreciation
68000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
6915000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
642000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19986000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8171381 shares
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
6599000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5020000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2012-12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001314102
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Trading Symbol
TradingSymbol
PSDV
dei Entity Registrant Name
EntityRegistrantName
pSivida Corp.
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3517000
us-gaap Investment Income Interest
InvestmentIncomeInterest
11000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
411760 shares
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3098000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-26000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
56000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22795000 shares
us-gaap Share Based Compensation
ShareBasedCompensation
606000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4784000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5238000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
284000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
606000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
59000
us-gaap Net Income Loss
NetIncomeLoss
-5159000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3278000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4669000
us-gaap Royalty Revenue
RoyaltyRevenue
774000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5100000
us-gaap Operating Expenses
OperatingExpenses
6376000
us-gaap Revenues
Revenues
1138000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
85000
us-gaap Increase Decrease In Accounts Receivable And Other Operating Assets
IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets
-310000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-70000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
1000
us-gaap License And Services Revenue
LicenseAndServicesRevenue
364000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4668000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
386000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
3000
us-gaap Depreciation
Depreciation
111000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
4585000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
606000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5229000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4846220 shares
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
8138000
CY2011Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-151000
CY2011Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20803000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.29
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4669000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3403000
psdv Share Based Compensation By Share Based Payment Award Options Granted Contractual Life
ShareBasedCompensationByShareBasedPaymentAwardOptionsGrantedContractualLife
10 years
psdv Milestone Payment Due Upon Approval By Fda
MilestonePaymentDueUponApprovalByFda
25000000
psdv Noncash Or Part Noncash Unpaid Property Plant Equipment And Other Assets
NoncashOrPartNoncashUnpaidPropertyPlantEquipmentAndOtherAssets
14000
psdv Number Of Options Vested During Period
NumberOfOptionsVestedDuringPeriod
625826 shares
CY2012Q3 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
694000
CY2012Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2494419 shares
CY2012Q3 psdv Term Of Warrants Issued
TermOfWarrantsIssued
5 Y
CY2012Q3 psdv Warrants Granted To Purchase Common Stock
WarrantsGrantedToPurchaseCommonStock
623605 shares
CY2012Q3 psdv Percentage Of Shares Of Common Stock Issued Under Terms Of Warrant Transactions
PercentageOfSharesOfCommonStockIssuedUnderTermsOfWarrantTransactions
0.25 pure
CY2012Q3 psdv Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
5400000
CY2011Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
CY2011Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
11000
CY2011Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1992000
CY2011Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-17643000
CY2011Q4 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
14830000
CY2011Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-144000
CY2011Q4 us-gaap Net Income Loss
NetIncomeLoss
-17460000
CY2011Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
139000
CY2011Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1451000
CY2011Q4 us-gaap Royalty Revenue
RoyaltyRevenue
426000
CY2011Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17604000
CY2011Q4 us-gaap Operating Expenses
OperatingExpenses
18273000
CY2011Q4 us-gaap Revenues
Revenues
630000
CY2011Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-44000
CY2011Q4 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
128000
CY2011Q4 us-gaap License And Services Revenue
LicenseAndServicesRevenue
204000
CY2011Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
819000
CY2011Q4 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
7000
CY2011Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
165000
CY2011Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17504000
CY2012Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2012Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.11
CY2012Q4 us-gaap Investment Income Interest
InvestmentIncomeInterest
4000
CY2012Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1575000
CY2012Q4 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3000
CY2012Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23297000 shares
CY2012Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2648000
CY2012Q4 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-8000
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-2608000
CY2012Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3000
CY2012Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1658000
CY2012Q4 us-gaap Royalty Revenue
RoyaltyRevenue
390000
CY2012Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2616000
CY2012Q4 us-gaap Operating Expenses
OperatingExpenses
3233000
CY2012Q4 us-gaap Revenues
Revenues
585000
CY2012Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-37000
CY2012Q4 us-gaap License And Services Revenue
LicenseAndServicesRevenue
195000
CY2012Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
194000
CY2012Q4 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-5000
CY2012Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
263000
CY2012Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2645000
CY2012Q4 psdv Number Of Patient Under Trial
NumberOfPatientUnderTrial
300 Patient

Files In Submission

Name View Source Status
0001193125-13-045326-index-headers.html Edgar Link pending
0001193125-13-045326-index.html Edgar Link pending
0001193125-13-045326.txt Edgar Link pending
0001193125-13-045326-xbrl.zip Edgar Link pending
d458338d10q.htm Edgar Link pending
d458338dex311.htm Edgar Link pending
d458338dex312.htm Edgar Link pending
d458338dex321.htm Edgar Link pending
d458338dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
psdv-20121231.xml Edgar Link completed
psdv-20121231.xsd Edgar Link pending
psdv-20121231_cal.xml Edgar Link unprocessable
psdv-20121231_def.xml Edgar Link unprocessable
psdv-20121231_lab.xml Edgar Link unprocessable
psdv-20121231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending